
"Sector" = median of Healthcare across 84 companies
Elevance Health, Inc. is a leading health benefits company headquartered in Indianapolis, Indiana. It operates through its subsidiaries, primarily Anthem, Inc., providing a wide range of health insurance plans and related services to individuals, families, employers, and government programs. The company is one of the largest managed care organizations in the United States, focusing on improving health outcomes and reducing costs through innovative care delivery and digital health solutions.
Elevance generates revenue primarily from premiums collected from members enrolled in its health plans. Its business segments include Commercial & Specialty Business, Government Business (Medicare, Medicaid, and Federal Health Products & Services), and Carelon (health services and pharmacy benefit management). The company also earns fees from administrative services and other health-related services. In the most recent quarter, revenue was $50.18 billion, with net income of $1.76 billion.
The company operates in the highly competitive Healthcare Plans industry within the Healthcare sector. Key competitors include UnitedHealth Group, Cigna, and Humana. Elevance differentiates itself through its integrated care model, strong focus on government-sponsored programs, and its Carelon subsidiary, which provides cost-effective health services. With a market cap of $85 billion and a P/E ratio of 16.59, it is considered a stable player in the managed care space.
Elevance serves a diverse customer base, including employer groups, individuals, Medicare and Medicaid beneficiaries, and federal employees. Its geographic focus is primarily the United States, where it operates in all 50 states through Blue Cross and Blue Shield licenses in several states. The company has over 46 million members across its health plans, with a significant presence in the commercial and government segments.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: June 2026 · 2026-06-30
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Jun 10, 2026 | $1.72 | Jun 25, 2026 | — |
| Mar 10, 2026 | $1.72 | Mar 25, 2026 | Quarterly |
| Dec 5, 2025 | $1.71 | Dec 19, 2025 | Quarterly |
| Sep 10, 2025 | $1.71 | Sep 25, 2025 | Quarterly |
| Jun 10, 2025 | $1.71 | Jun 25, 2025 | Quarterly |
| Mar 10, 2025 | $1.71 | Mar 25, 2025 | Quarterly |
| Dec 5, 2024 | $1.63 | Dec 20, 2024 | Quarterly |
| Sep 10, 2024 | $1.63 | Sep 25, 2024 | Quarterly |
| Jun 10, 2024 | $1.63 | Jun 25, 2024 | Quarterly |
| Mar 7, 2024 | $1.63 | Mar 22, 2024 | Quarterly |
| Dec 5, 2023 | $1.48 | Dec 21, 2023 | Quarterly |
| Sep 7, 2023 | $1.48 | Sep 22, 2023 | Quarterly |
| Jun 8, 2023 | $1.48 | Jun 23, 2023 | Quarterly |
| Mar 9, 2023 | $1.48 | Mar 24, 2023 | Quarterly |
| Dec 2, 2022 | $1.28 | Dec 21, 2022 | Quarterly |
| Sep 8, 2022 | $1.28 | Sep 23, 2022 | Quarterly |
| Jun 9, 2022 | $1.28 | Jun 24, 2022 | Quarterly |
| Mar 9, 2022 | $1.28 | Mar 25, 2022 | Quarterly |
| Dec 2, 2021 | $1.13 | Dec 21, 2021 | Quarterly |
| Sep 9, 2021 | $1.13 | Sep 24, 2021 | Quarterly |
| Jun 9, 2021 | $1.13 | Jun 25, 2021 | Quarterly |
| Mar 9, 2021 | $1.13 | Mar 25, 2021 | Quarterly |
| Dec 4, 2020 | $0.95 | Dec 22, 2020 | Quarterly |
| Sep 9, 2020 | $0.95 | Sep 25, 2020 | Quarterly |
Wrqti brings Elevance Health, Inc. data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with Elevance Health, Inc.:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: June 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.